In contrast to the common paradigm that CHK1 inhibitor can be used as a radiosensitizer, in this study we report that CHK1 inhibitor, as a single agent, can specifically target RBCC via regulation of RS (Figure 7), reducing the growth of tumor cells in vitro and in vivo. This evidence concerns the gene CHEK1 and neoplasm.